Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ PennsylvaniafiledCriticalNovartis Ag
Publication of AR098848A1publicationCriticalpatent/AR098848A1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Composiciones y métodos para tratar enfermedades asociadas con la expresión de mesotelina. También se refiere a un receptor de antígeno quimérico (CAR) específico a mesotelina, vectores que codifican el mismo, y células T recombinantes que comprenden el CAR de mesotelina. También incluye métodos de administración de una célula T modificada genéticamente que expresa un CAR que comprende un dominio de unión a mesotelina. Molécula aislada de ácido nucleico. Dominio de unión.Compositions and methods to treat diseases associated with the expression of mesothelin. It also refers to a mesothelin-specific chimeric antigen (CAR) receptor, vectors encoding it, and recombinant T cells comprising the mesothelin CAR. It also includes methods of administration of a genetically modified T cell expressing a CAR comprising a mesothelin binding domain. Isolated nucleic acid molecule. Union Domain
ARP140104779A2013-12-192014-12-19
RECEPTORS OF CHEMICAL ANTIGEN OF HUMAN MESOTHELINE AND USES OF THE SAME
AR098848A1
(en)